World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   170 records for 61 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7
Recruitment statusProspective RegistrationMain ID Public TitleDate of RegistrationResults available
AuthorisedYesEUCTR2017-001769-26-HU
STELLA – A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) - STELLA
26/09/2017 
RecruitingNoCTRI/2017/09/009894
Heat therapy(agnikarma) in Tennis Elbow
22-09-2017 
Not recruitingYesNCT03296163
A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
19/09/2017 
RecruitingYesNCT03289273
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
18/09/2017 
Not AvailableYesEUCTR2016-004322-42-Outside-EU/EEA
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)”.
31/08/2017 
RecruitingYesDRKS00012686
Smartphone-based intervention (S.M.I.L.E.R.S.) to reduce mild to moderate depressive symptoms in Arabic-speaking clients
21/08/2017 
RecruitingYesNCT03082976
Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region
27/02/2017 
AuthorisedYesEUCTR2016-003370-40-GB
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease 09/12/2016 
AuthorisedYesEUCTR2016-003467-19-BE
safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2016-003467-19-ES Safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 10/02/2017 
AuthorisedEUCTR2016-003467-19-HU safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 25/11/2016 
AuthorisedEUCTR2016-003467-19-GR safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 03/01/2017 
AuthorisedEUCTR2016-003467-19-SI safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 09/05/2017 
AuthorisedEUCTR2016-003467-19-PT safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 14/12/2016 
AuthorisedEUCTR2016-003467-19-FI safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 07/04/2017 
AuthorisedEUCTR2016-003467-19-AT safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 03/02/2017 
AuthorisedEUCTR2016-003467-19-PL safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 06/04/2017 
AuthorisedEUCTR2016-003467-19-NL safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 23/11/2016 
AuthorisedEUCTR2016-003467-19-NO safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 24/02/2017 
AuthorisedEUCTR2016-003467-19-GB safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre / postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 07/11/2016 
AuthorisedEUCTR2016-003467-19-BG safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 07/12/2016 
AuthorisedEUCTR2016-003467-19-DK safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 16/02/2017 
AuthorisedEUCTR2016-003467-19-CZ safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease 02/02/2017 
20/10/2016 
RecruitingYesNCT02941926
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC 20/10/2016 
      
1 2 3 4 5 6 7
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history